scholarly journals Efficacy and Safety of Immunomodulation with Fast Withdrawal of Immunosuppression (FWI) and Donor Lymphocyte Infusions (DLI) for Prevention of Relapse in Children Receiving Allogeneic Hematopoietic Stem Cell Transplant (HCT) for Hematologic Malignancies

2013 ◽  
Vol 19 (2) ◽  
pp. S325
Author(s):  
Biljana Horn ◽  
Aleksandra Petrovic ◽  
Christopher C. Dvorak ◽  
Morton J. Cowan ◽  
Justin T. Wahlstrom ◽  
...  
Cancers ◽  
2021 ◽  
Vol 13 (2) ◽  
pp. 295
Author(s):  
Matthew J. Olnes

The era of immunotherapy for hematologic malignancies began with the first allogeneic hematopoietic stem cell transplant (HSCT) study published by E [...]


2021 ◽  
pp. 204589402110277
Author(s):  
Toshikazu D Tanaka ◽  
David C Ishizawar ◽  
Takeshi Saito ◽  
Akira Yoshii ◽  
Michihiro Yoshimura

A 46-year-old man who had undergone hematopoietic stem cell transplant (HSCT) twice because of acute lymphoblastic leukemia with recurrence presented with dyspnea, leading to a diagnosis of pulmonary arterial hypertension (PAH) which was quickly and effectively treated with the PDE-5 inhibitor tadalafil. To our knowledge, PAH related to hematologic malignancies requiring HSCT is rarely reported. Importantly, the present case suggests that early diagnosis and treatment with a pulmonary vasodilator, such as tadalafil, can greatly decrease pulmonary vascular resistance in patients with severe PAH after HSCT and can then improve other symptoms. Accordingly, pulmonary vascular disease should be considered if respiratory symptoms develop following HSCT, because treatment with pulmonary vasodilator may lead to significant improvement in PAH.


Sign in / Sign up

Export Citation Format

Share Document